Equities Analysts Offer Predictions for DNLI FY2027 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for Denali Therapeutics in a research note issued to investors on Thursday, March 26th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($1.41) per share for the year, up from their prior estimate of ($1.52). HC Wainwright currently has a “Buy” rating and a $42.00 price target on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2028 earnings at ($0.18) EPS, FY2029 earnings at $0.97 EPS and FY2030 earnings at $2.44 EPS.

Several other equities research analysts have also recently weighed in on the stock. BTIG Research boosted their price target on shares of Denali Therapeutics from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. The Goldman Sachs Group increased their price objective on shares of Denali Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. UBS Group initiated coverage on shares of Denali Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating for the company. Wedbush reduced their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, December 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Denali Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $34.82.

Denali Therapeutics Price Performance

NASDAQ DNLI opened at $18.16 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.16 and a current ratio of 9.16. The company has a market capitalization of $2.88 billion, a P/E ratio of -6.11 and a beta of 1.02. Denali Therapeutics has a one year low of $10.57 and a one year high of $23.77. The stock has a 50 day moving average price of $20.43 and a 200-day moving average price of $17.87.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same period in the previous year, the firm posted ($0.67) EPS.

Insiders Place Their Bets

In other Denali Therapeutics news, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the transaction, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. The trade was a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ryan J. Watts sold 35,198 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the transaction, the chief executive officer owned 296,833 shares in the company, valued at $4,897,744.50. This trade represents a 10.60% decrease in their position. The disclosure for this sale is available in the SEC filing. 12.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNLI. Headlands Technologies LLC bought a new stake in Denali Therapeutics in the second quarter worth about $26,000. Johnson Financial Group Inc. bought a new position in shares of Denali Therapeutics during the third quarter valued at approximately $29,000. State of Wyoming purchased a new stake in shares of Denali Therapeutics in the second quarter worth approximately $29,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Denali Therapeutics in the fourth quarter worth approximately $57,000. Finally, Quarry LP bought a new stake in shares of Denali Therapeutics during the 3rd quarter worth approximately $64,000. 92.92% of the stock is currently owned by institutional investors.

Key Headlines Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.